SCHEMBL1554079

SCHEMBL1554079

O=C1COC(=O)C1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL791435 0.67
SCHEMBL31429176 0.67
SCHEMBL5027915 0.67
SCHEMBL818856 0.67
SCHEMBL11673253 0.63
SCHEMBL5924311 0.62
SCHEMBL10175674 0.62
SCHEMBL368280 0.62
SCHEMBL979504 0.61
SCHEMBL1298896 0.60 ATM (0.31)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0153615-B1 PROCESS FOR THE PREPARATION OF TETRONIC ACID LONZA AG (CH) 1989-04-26 EP claimed
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4735426-A1 HETEROAROMATIC DHODH INHIBITORS Immunic AG (DE) 2026-05-06 EP disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-20250230171-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2025-07-17 US disclosed
WO-2025003402-A1 HETEROAROMATIC DHODH INHIBITORS IMMUNIC AG (DE) 2025-01-02 WO disclosed
WO-2024211836-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-20240043450-A1 NEW COMPOUND JANSSEN PHARMACEUTICA NV (BE) 2024-02-08 US disclosed
EP-4217347-A1 NEW COMPOUNDS JANSSEN Pharmaceutica NV (BE) 2023-08-02 EP disclosed
EP-2102199-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS AstraZeneca AB (SE) 2009-09-23 EP disclosed
EP-2064209-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY AstraZeneca AB (SE) 2009-06-03 EP disclosed
WO-2008068470-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS ASTRAZENECA AB (SE) 2008-06-12 WO disclosed
US-20080132546-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-05 US disclosed
WO-2008020227-A2 ANTIBACTERIAL PYRROLECARBOXAMIDES ASTRAZENECA AB (SE) 2008-02-21 WO disclosed
WO-2008020222-A1 PYRROLE DERIVATIVES WITH ANTIBACTERIAL ACTIVITY ASTRAZENECA AB (SE) 2008-02-21 WO disclosed
US-5808014-A Process for the preparation of arlazotetronic acid derivatives LONZA, AG (CH) 1998-09-15 US disclosed
EP-0827958-A1 Method for the preparation of arylazotetronic acid derivatives LONZA AG (CH) 1998-03-11 EP disclosed
EP-0418020-A2 Cephalosporinderivatives, process for their preparation and pharmaceutical compositions BEECHAM GROUP PLC (GB) 1991-03-20 EP disclosed
EP-0153615-A1 Process for the preparation of tetronic acid LONZA AG (CH) 1985-09-04 EP disclosed